Resistance to Raf inhibition in cancer

Publication date: March 2014 Source:Drug Discovery Today: Technologies, Volume 11 Author(s): H. Eirik Haarberg , Keiran S.M. Smalley The use of small molecule BRAF inhibitors has revolutionized the treatment of advanced melanoma. Despite this, resistance is commonplace and associated with a median progression-free survival of >5 months. Major resistance mechanisms include reactivation of the MAPK pathway and increased PI3K/AKT signaling. Here we review some of the combination therapeutic strategies currently undergoing evaluation for the management of acquired drug resistance in melanoma.
Source: Drug Discovery Today: Technologies - Category: Drugs & Pharmacology Source Type: research